September 22, 2021
Dear Rett Syndrome Community,
Taysha recently hosted an educational event on Rett syndrome for the investment community. This was a great opportunity for investors to learn about the disease and its natural history, the burden of disease from the patient and caregiver perspective, as well as updates for TSHA-102, Taysha’s Rett syndrome investigational gene therapy program.
This was also an opportunity to hear perspectives from respected patient advocacy and physician leaders in the Rett syndrome community. They provided an overview of the natural history of Rett syndrome and discussed the journey that patients and their families face with the condition. The event also featured Steven Gray, Ph.D., Associate Professor in the Department of Pediatrics at UT Southwestern and Chief Scientific Advisor at Taysha Gene Therapies, as well as Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Taysha’s Chief Medical Officer and Head of R&D.
“Perspectives from physicians, patients, caregivers and researchers provide an important understanding of the true unmet need in Rett syndrome. Each person is instrumental in our efforts to bring new medicines to patients. We are grateful to these leaders for shedding light on meaningful insights about Rett syndrome.”
– Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM Chief Medical Office and Head of Research & Development at Taysha Gene
We are committed to the Rett syndrome community and are grateful for the support that advocates, and families continue to give our team at Taysha. We look forward to providing you with updates related to Taysha’s Rett syndrome program (TSHA-102) through our Rett syndrome advocacy partners.
Your Rare Ally, The Taysha Team